Lactic acid bacteria: Reviewing the potential of a promising delivery live vector for biomedical purposes

Microbial Cell Factories

Volumn 14, Issue 1, 2015, Pages

  Cano Garrido, Olivia ^a,b   Seras Franzoso, Joaquin ^a,b   Garcia Fruitós, Elena ^a,b,c  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^c IRTA   (Spain)

Author keywords

Delivery vector; Lactic acid bacteria; Mucosal; QPS; Therapy; Treatment

Indexed keywords

BACTERIAL VECTOR; CATALASE; CYTOSINE DEAMINASE; ENDOSTATIN; GAG PROTEIN; GLUCAGON LIKE PEPTIDE 1; GLUTAMATE DECARBOXYLASE 65; INTESTINAL TREFOIL FACTOR; LEPTIN; LUCIFERASE; PNEUMOCOCCAL SURFACE PROTEIN A; PROINSULIN; PROTEIN ARA H 2; PROTEIN CWP2; PROTEIN DER P2; PROTEIN LACK; PROTEIN SCFV; PROTEIN VP1; PROTEIN VP2; PROTEIN VP8; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 27; RECOMBINANT PROTEIN; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; SALCATONIN; SUPEROXIDE DISMUTASE; TETANUS TOXIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS ANTIGEN; VIRUS SPIKE PROTEIN; LACTIC ACID; PROBIOTIC AGENT;

BACILLUS SUBTILIS; BIFIDOBACTERIUM ADOLESCENTIS; BIFIDOBACTERIUM BREVE; BIFIDOBACTERIUM LONGUM; BODY WEIGHT DISORDER; BREAST CANCER; COLORECTAL CANCER; DRUG DELIVERY SYSTEM; DRUG INDICATION; DRUG RESPONSE; ENTEROVIRUS INFECTION; GIARDIASIS; HOUSE DUST ALLERGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCALCEMIA; INFLAMMATORY BOWEL DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; LACTIC ACID BACTERIUM; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS GASSERI; LACTOBACILLUS JENSENII; LACTOBACILLUS PARACASEI; LACTOBACILLUS PLANTARUM; LACTOCOCCUS LACTIS; LEISHMANIASIS; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS NECROSIS; PEANUT ALLERGY; PNEUMOCOCCAL INFECTION; REVIEW; ROTAVIRUS INFECTION; SEVERE ACUTE RESPIRATORY SYNDROME; STREPTOCOCCUS GORDONII; STREPTOCOCCUS INFECTION; TETANUS; UTERINE CERVIX CANCER; AUTOIMMUNE DISEASES; GASTROINTESTINAL TRACT; GENE VECTOR; GENETICS; GRAM POSITIVE BACTERIUM; METABOLIC ENGINEERING; METABOLISM; MICROBIOLOGY; NEOPLASMS; PHYSIOLOGY; PROCEDURES; TRANSGENIC ORGANISM;

AUTOIMMUNE DISEASES; DRUG DELIVERY SYSTEMS; GASTROINTESTINAL TRACT; GENETIC VECTORS; GRAM-POSITIVE BACTERIA; HUMANS; LACTIC ACID; METABOLIC ENGINEERING; NEOPLASMS; ORGANISMS, GENETICALLY MODIFIED; PROBIOTICS; RECOMBINANT PROTEINS;

EID: 84941647193     PISSN: None     EISSN: 14752859     Source Type: Journal    
DOI: 10.1186/s12934-015-0313-6     Document Type: Review

References (115)

1. Ferrer-Miralles N, Domingo-Espin J, Corchero JL, Vazquez E, Villaverde A (2009) Microbial factories for recombinant pharmaceuticals. Microb Cell Fact 8:17
2. Hillery AM (2011) Drug delivery and targeting: for pharmacists and pharmaceutical scientists. Tailor & Francis, UK
3. Rueda F, Cano-Garrido O, Mamat U, Wilke K, Seras-Franzoso J, Garcia-Fruitos E, Villaverde A (2014) Production of functional inclusion bodies in endotoxin-free Escherichia coli. Appl Microbiol Biotechnol 98:9229-9238
4. Wells JM (2011) Immunomodulatory mechanisms of lactobacilli. Microb Cell Factories 10(Suppl 1):S17
5. Gareau MG, Sherman PM, Walker WA (2010) Probiotics and the gut microbiota in intestinal health and disease. Nat Rev Gastroenterol Hepatol 7:503-514
6. Konings WN, Kok J, Kuipers OP, Poolman B (2000) Lactic acid bacteria: the bugs of the new millennium. Curr Opin Microbiol 3:276-282
7. Ross RP, Morgan S, Hill C (2002) Preservation and fermentation: past, present and future. Int J Food Microbiol 79:3-16
8. Salminen S, Nybom S, Meriluoto J, Collado MC, Vesterlund S, El-Nezami H (2010) Interaction of probiotics and pathogens-benefits to human health? Curr Opin Biotechnol 21:157-167
9. Garcia-Fruitos E (2012) Lactic acid bacteria: a promising alternative for recombinant protein production. Microb Cell Fact 11:157
10. LeBlanc JG, Aubry C, Cortes-Perez NG, de Moreno de LeBlanc A, Vergnolle N, Langella P, Azevedo V, Chatel JM, Miyoshi A, Bermudez-Humaran LG (2013) Mucosal targeting of therapeutic molecules using genetically modified lactic acid bacteria: an update. FEMS Microbiol Lett 344:1-9
11. Bermudez-Humaran LG, Aubry C, Motta JP, Deraison C, Steidler L, Vergnolle N, Chatel JM, Langella P (2013) Engineering lactococci and lactobacilli for human health. Curr Opin Microbiol 16:278-283
12. Mierau I, Kleerebezem M (2005) 10 years of the nisin-controlled gene expression system (NICE) in Lactococcus lactis. Appl Microbiol Biotechnol 68:705-717
13. Wells J (2011) Mucosal vaccination and therapy with genetically modified lactic acid bacteria. Annu Rev Food Sci Technol 2:423-445
14. Desmond C, Fitzgerald GF, Stanton C, Ross RP (2004) Improved stress tolerance of GroESL-overproducing Lactococcus lactis and probiotic Lactobacillus paracasei NFBC 338. Appl Environ Microbiol 70:5929-5936
15. Benbouziane B, Ribelles P, Aubry C, Martin R, Kharrat P, Riazi A, Langella P, Bermudez-Humaran LG (2013) Development of a Stress-Inducible Controlled Expression (SICE) system in Lactococcus lactis for the production and delivery of therapeutic molecules at mucosal surfaces. J Biotechnol 168:120-129
16. Moore RJ, Stewart DJ, Lund K, Hodgson AL (2001) Vaccination against ovine footrot using a live bacterial vector to deliver basic protease antigen. FEMS Microbiol Lett 194:193-196
17. Baumgart DC, Carding SR (2007) Inflammatory bowel disease: cause and immunobiology. Lancet 369:1627-1640
18. Bernstein CN (2015) Treatment of IBD: where we are and where we are going. Am J Gastroenterol 110:114-126
19. Strober W, Fuss I, Mannon P (2007) The fundamental basis of inflammatory bowel disease. J Clin Invest 117:514-521
20. Papa A, Mocci G, Bonizzi M, Felice C, Andrisani G, Papa G, Gasbarrini A (2009) Biological therapies for inflammatory bowel disease: controversies and future options. Expert Rev Clin Pharmacol 2:391-403
21. Foligne B, Dessein R, Marceau M, Poiret S, Chamaillard M, Pot B, Simonet M, Daniel C (2007) Prevention and treatment of colitis with Lactococcus lactis secreting the immunomodulatory Yersinia LcrV protein. Gastroenterology 133:862-874
22. Vandenbroucke K, de Haard H, Beirnaert E, Dreier T, Lauwereys M, Huyck L, Van Huysse J, Demetter P, Steidler L, Remaut E et al (2010) Orally administered L. lactis secreting an anti-TNF nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol 3:49-56
23. Vandenbroucke K, Hans W, Van Huysse J, Neirynck S, Demetter P, Remaut E, Rottiers P, Steidler L (2004) Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice. Gastroenterology 127:502-513
24. Rochat T, Miyoshi A, Gratadoux JJ, Duwat P, Sourice S, Azevedo V, Langella P (2005) High-level resistance to oxidative stress in Lactococcus lactis conferred by Bacillus subtilis catalase KatE. Microbiology 151:3011-3018
25. Rochat T, Bermudez-Humaran L, Gratadoux JJ, Fourage C, Hoebler C, Corthier G, Langella P (2007) Anti-inflammatory effects of Lactobacillus casei BL23 producing or not a manganese-dependant catalase on DSS-induced colitis in mice. Microb Cell Fact 6:22
26. Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon JP, van Deventer SJ, Neirynck S, Peppelenbosch MP, Steidler L (2006) A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol 4:754-759
27. Van Assche G, Vermeire S, Rutgeerts P (2009) Infliximab therapy for patients with inflammatory bowel disease: 10 years on. Eur J Pharmacol 623(Suppl 1):S17-S25
28. Riegert-Johnson DL, Godfrey JA, Myers JL, Hubmayr RD, Sandborn WJ, Loftus EV Jr (2002) Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion. Inflamm Bowel Dis 8:186-191
29. Kakavas S, Balis E, Lazarou V, Kouvela M, Tatsis G (2013) Respiratory failure due to infliximab induced interstitial lung disease. Heart Lung 42:480-482
30. Vaz JL, Andrade CA, Pereira AC, Martins Mde F, Levy RA (2013) Systematic review of infliximab-induced autoantibodies and systemic lupus erythematosus. Rev Bras Reumatol 53:358-364
31. Huibregtse IL, Snoeck V, de Creus A, Braat H, De Jong EC, Van Deventer SJ, Rottiers P (2007) Induction of ovalbumin-specific tolerance by oral administration of Lactococcus lactis secreting ovalbumin. Gastroenterology 133:517-528
32. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, Fiers W, Remaut E (2000) Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289:1352-1355
33. Steidler L, Neirynck S, Huyghebaert N, Snoeck V, Vermeire A, Goddeeris B, Cox E, Remon JP, Remaut E (2003) Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat Biotechnol 21:785-789
34. Rottiers P, De Smedt T, Steidler L (2009) Modulation of gut-associated lymphoid tissue functions with genetically modified Lactococcus lactis. Int Rev Immunol 28:465-486
35. Hanson ML, Hixon JA, Li W, Felber BK, Anver MR, Stewart CA, Janelsins BM, Datta SK, Shen W, McLean MH, Durum SK (2014) Oral delivery of IL-27 recombinant bacteria attenuates immune colitis in mice. Gastroenterology 146(210-221):e213
36. Motta JP, Bermudez-Humaran LG, Deraison C, Martin L, Rolland C, Rousset P, Boue J, Dietrich G, Chapman K, Kharrat P et al (2012) Food-grade bacteria expressing elafin protect against inflammation and restore colon homeostasis. Sci Transl Med 4:158ra144
37. Bermudez-Humaran LG, Motta JP, Aubry C, Kharrat P, Rous-Martin L, Sallenave JM, Deraison C, Vergnolle N, Langella P (2015) Serine protease inhibitors protect better than IL-10 and TGF-beta anti-inflammatory cytokines against mouse colitis when delivered by recombinant lactococci. Microb Cell Fact 14:26
38. de Moreno de LeBlanc A, Del Carmen S, Chatel JM, Miyoshi A, Azevedo V, Langella P, Bermudez-Humaran LG, LeBlanc JG (2015) Current review of genetically modified lactic acid bacteria for the prevention and treatment of colitis using murine models. Gastroenterol Res Pract 2015:146972
39. Watterlot L, Rochat T, Sokol H, Cherbuy C, Bouloufa I, Lefevre F, Gratadoux JJ, Honvo-Hueto E, Chilmonczyk S, Blugeon S et al (2010) Intragastric administration of a superoxide dismutase-producing recombinant Lactobacillus casei BL23 strain attenuates DSS colitis in mice. Int J Food Microbiol 144:35-41
40. Carroll IM, Andrus JM, Bruno-Barcena JM, Klaenhammer TR, Hassan HM, Threadgill DS (2007) Anti-inflammatory properties of Lactobacillus gasseri expressing manganese superoxide dismutase using the interleukin 10-deficient mouse model of colitis. Am J Physiol Gastrointest Liver Physiol 293:G729-G738
41. Ng DT, Sarkar CA (2011) Nisin-inducible secretion of a biologically active single-chain insulin analog by Lactococcus lactis NZ9000. Biotechnol Bioeng 108:1987-1996
42. Agarwal P, Khatri P, Billack B, Low WK, Shao J (2014) Oral delivery of glucagon like peptide-1 by a recombinant Lactococcus lactis. Pharm Res 31:3404-3414
43. Ma Y, Liu J, Hou J, Dong Y, Lu Y, Jin L, Cao R, Li T, Wu J (2014) Oral administration of recombinant Lactococcus lactis expressing HSP65 and tandemly repeated P277 reduces the incidence of type I diabetes in non-obese diabetic mice. PLoS One 9:e105701
44. Takiishi T, Korf H, Van Belle TL, Robert S, Grieco FA, Caluwaerts S, Galleri L, Spagnuolo I, Steidler L, Van Huynegem K et al (2012) Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice. J Clin Invest 122:1717-1725
45. Robert S, Gysemans C, Takiishi T, Korf H, Spagnuolo I, Sebastiani G, Van Huynegem K, Steidler L, Caluwaerts S, Demetter P et al (2014) Oral delivery of glutamic acid decarboxylase (GAD)-65 and IL10 by Lactococcus lactis reverses diabetes in recent-onset NOD mice. Diabetes 63:2876-2887
46. Robert S, Van Huynegem K, Gysemans C, Mathieu C, Rottiers P, Steidler L (2015) Trimming of two major type 1 diabetes driving antigens, GAD65 and IA-2, allows for successful expression in Lactococcus lactis. Benef Microbes 6:591-601
47. Aggarwal BB, Vijayalekshmi RV, Sung B (2009) Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res 15:425-430
48. Azcarate-Peril MA, Sikes M, Bruno-Barcena JM (2011) The intestinal microbiota, gastrointestinal environment and colorectal cancer: a putative role for probiotics in prevention of colorectal cancer? Am J Physiol Gastrointest Liver Physiol 301:G401-G424
49. Le Leu RK, Hu Y, Brown IL, Woodman RJ, Young GP (2010) Synbiotic intervention of Bifidobacterium lactis and resistant starch protects against colorectal cancer development in rats. Carcinogenesis 31:246-251
50. Yamazaki K, Tsunoda A, Sibusawa M, Tsunoda Y, Kusano M, Fukuchi K, Yamanaka M, Kushima M, Nomoto K, Morotomi M (2000) The effect of an oral administration of Lactobacillus casei strain shirota on azoxymethane-induced colonic aberrant crypt foci and colon cancer in the rat. Oncol Rep 7:977-982
51. Kulkarni N, Reddy BS (1994) Inhibitory effect of Bifidobacterium longum cultures on the azoxymethane-induced aberrant crypt foci formation and fecal bacterial beta-glucuronidase. Proc Soc Exp Biol Med 207:278-283
52. McIntosh GH, Royle PJ, Playne MJ (1999) A probiotic strain of L. acidophilus reduces DMH-induced large intestinal tumors in male Sprague-Dawley rats. Nutr Cancer 35:153-159
53. Goldin BR, Gualtieri LJ, Moore RP (1996) The effect of Lactobacillus GG on the initiation and promotion of DMH-induced intestinal tumors in the rat. Nutr Cancer 25:197-204
54. Lan A, Lagadic-Gossmann D, Lemaire C, Brenner C, Jan G (2007) Acidic extracellular pH shifts colorectal cancer cell death from apoptosis to necrosis upon exposure to propionate and acetate, major end-products of the human probiotic propionibacteria. Apoptosis 12:573-591
55. Malmgren RA, Flanigan CC (1955) Localization of the vegetative form of Clostridium tetani in mouse tumors following intravenous spore administration. Cancer Res 15:473-478
56. Kimura NT, Taniguchi S, Aoki K, Baba T (1980) Selective localization and growth of Bifidobacterium bifidum in mouse tumors following intravenous administration. Cancer Res 40:2061-2068
57. Fujimori M (2006) Genetically engineered bifidobacterium as a drug delivery system for systemic therapy of metastatic breast cancer patients. Breast Cancer 13:27-31
58. Li X, Fu GF, Fan YR, Liu WH, Liu XJ, Wang JJ, Xu GX (2003) Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: selective inhibitor of angiogenesis and hypoxic tumor growth. Cancer Gene Ther 10:105-111
59. Cronin M, Morrissey D, Rajendran S, El Mashad SM, van Sinderen D, O'Sullivan GC, Tangney M (2010) Orally administered bifidobacteria as vehicles for delivery of agents to systemic tumors. Mol Ther 18:1397-1407
60. de Moreno de LeBlanc A, LeBlanc JG, Perdigon G, Miyoshi A, Langella P, Azevedo V, Sesma F (2008) Oral administration of a catalase-producing Lactococcus lactis can prevent a chemically induced colon cancer in mice. J Med Microbiol 57:100-105
61. Rangel-Colmenero BR, Gomez-Gutierrez JG, Villatoro-Hernandez J, Zavala-Flores LM, Quistian-Martinez D, Rojas-Martinez A, Arce-Mendoza AY, Guzman-Lopez S, Montes-de-Oca-Luna R, Saucedo-Cardenas O (2014) Enhancement of Ad-CRT/E7-mediated antitumor effect by preimmunization with L. lactis expressing HPV-16 E7. Viral Immunol 27:463-467
62. Li Y, Li X, Liu H, Zhuang S, Yang J, Zhang F (2014) Intranasal immunization with recombinant Lactococci carrying human papillomavirus E7 protein and mouse interleukin-12 DNA induces E7-specific antitumor effects in C57BL/6 mice. Oncol Lett 7:576-582
63. Ribelles P, Benbouziane B, Langella P, Suarez JE, Bermudez-Humaran LG (2013) Protection against human papillomavirus type 16-induced tumors in mice using non-genetically modified lactic acid bacteria displaying E7 antigen at its surface. Appl Microbiol Biotechnol 97:1231-1239
64. Koo OK, Amalaradjou MA, Bhunia AK (2012) Recombinant probiotic expressing Listeria adhesion protein attenuates Listeria monocytogenes virulence in vitro. PLoS One 7:e29277
65. Formal SB, Baron LS, Kopecko DJ, Washington O, Powell C, Life CA (1981) Construction of a potential bivalent vaccine strain: introduction of Shigella sonnei form I antigen genes into the galE Salmonella typhi Ty21a typhoid vaccine strain. Infect Immun 34:746-750
66. Bermudez-Humaran LG, Kharrat P, Chatel JM, Langella P (2011) Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines. Microb Cell Fact 10(Suppl 1):S4
67. Bahey-El-Din M, Gahan CG, Griffin BT (2010) Lactococcus lactis as a cell factory for delivery of therapeutic proteins. Curr Gene Ther 10:34-45
68. Kruger C, Hu Y, Pan Q, Marcotte H, Hultberg A, Delwar D, van Dalen PJ, Pouwels PH, Leer RJ, Kelly CG et al (2002) In situ delivery of passive immunity by lactobacilli producing single-chain antibodies. Nat Biotechnol 20:702-706
69. Chang TL, Chang CH, Simpson DA, Xu Q, Martin PK, Lagenaur LA, Schoolnik GK, Ho DD, Hillier SL, Holodniy M et al (2003) Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4. Proc Natl Acad Sci USA 100:11672-11677
70. Reveneau N, Geoffroy MC, Locht C, Chagnaud P, Mercenier A (2002) Comparison of the immune responses induced by local immunizations with recombinant Lactobacillus plantarum producing tetanus toxin fragment C in different cellular locations. Vaccine 20:1769-1777
71. Moeini H, Rahim RA, Omar AR, Shafee N, Yusoff K (2011) Lactobacillus acidophilus as a live vehicle for oral immunization against chicken anemia virus. Appl Microbiol Biotechnol 90:77-88
72. Maassen CB, Laman JD, den Bak-Glashouwer MJ, Tielen FJ, van Holten-Neelen JC, Hoogteijling L, Antonissen C, Leer RJ, Pouwels PH, Boersma WJ, Shaw DM (1999) Instruments for oral disease-intervention strategies: recombinant Lactobacillus casei expressing tetanus toxin fragment C for vaccination or myelin proteins for oral tolerance induction in multiple sclerosis. Vaccine 17:2117-2128
73. Lee P, Faubert GM (2006) Oral immunization of BALB/c mice by intragastric delivery of Streptococcus gordonii-expressing Giardia cyst wall protein 2 decreases cyst shedding in challenged mice. FEMS Microbiol Lett 265:225-236
74. Baek JO, Seo JW, Kwon O, Park SM, Kim CH, Kim IH (2012) Production of human papillomavirus type 33 L1 major capsid protein and virus-like particles from Bacillus subtilis to develop a prophylactic vaccine against cervical cancer. Enzyme Microb Technol 50:173-180
75. Zhang M, Zhang H, Li Y, Qi W, Wang X, Wang J (2013) Inhibitory effect of Lactobacillus acidophilus on Helicobacter hepaticus in vitro. World J Microbiol Biotechnol 29:499-504
76. Hongying F, Xianbo W, Fang Y, Yang B, Beiguo L (2014) Oral immunization with recombinant Lactobacillus acidophilus expressing the adhesin Hp0410 of Helicobacter pylori induces mucosal and systemic immune responses. Clin Vaccine Immunol 21:126-132
77. Seegers JF (2002) Lactobacilli as live vaccine delivery vectors: progress and prospects. Trends Biotechnol 20:508-515
78. de Vos WM (2011) Systems solutions by lactic acid bacteria: from paradigms to practice. Microb Cell Fact 10(Suppl 1):S2
79. Holmes AR, Gilbert C, Wells JM, Jenkinson HF (1998) Binding properties of Streptococcus gordonii SspA and SspB (antigen I/II family) polypeptides expressed on the cell surface of Lactococcus lactis MG1363. Infect Immun 66:4633-4639
80. Savijoki K, Kahala M, Palva A (1997) High level heterologous protein production in Lactococcus and Lactobacillus using a new secretion system based on the Lactobacillus brevis S-layer signals. Gene 186:255-262
81. Zhang ZH, Jiang PH, Li NJ, Shi M, Huang W (2005) Oral vaccination of mice against rodent malaria with recombinant Lactococcus lactis expressing MSP-1(19). World J Gastroenterol 11:6975-6980
82. Kajikawa A, Zhang L, Long J, Nordone S, Stoeker L, LaVoy A, Bumgardner S, Klaenhammer T, Dean G (2012) Construction and immunological evaluation of dual cell surface display of HIV-1 gag and Salmonella enterica serovar Typhimurium FliC in Lactobacillus acidophilus for vaccine delivery. Clin Vaccine Immunol 19:1374-1381
83. Lopez P, Gueimonde M, Margolles A, Suarez A (2010) Distinct bifidobacterium strains drive different immune responses in vitro. Int J Food Microbiol 138:157-165
84. Ruiz L, Alvarez-Martin P, Mayo B, de los Reyes-Gavilan CG, Gueimonde M, Margolles A (2012) Controlled gene expression in bifidobacteria by use of a bile-responsive element. Appl Environ Microbiol 78:581-585
85. Andersen KK, Marcotte H, Alvarez B, Boyaka PN, Hammarstrom L (2011) In situ gastrointestinal protection against anthrax edema toxin by single-chain antibody fragment producing lactobacilli. BMC Biotechnol 11:126
86. Mohamadzadeh M, Duong T, Sandwick SJ, Hoover T, Klaenhammer TR (2009) Dendritic cell targeting of Bacillus anthracis protective antigen expressed by Lactobacillus acidophilus protects mice from lethal challenge. Proc Natl Acad Sci USA 106:4331-4336
87. Pant N, Hultberg A, Zhao Y, Svensson L, Pan-Hammarstrom Q, Johansen K, Pouwels PH, Ruggeri FM, Hermans P, Frenken L et al (2006) Lactobacilli expressing variable domain of llama heavy-chain antibody fragments (lactobodies) confer protection against rotavirus-induced diarrhea. J Infect Dis 194:1580-1588
88. Hugentobler F, Di Roberto RB, Gillard J, Cousineau B (2012) Oral immunization using live Lactococcus lactis co-expressing LACK and IL-12 protects BALB/c mice against Leishmania major infection. Vaccine 30:5726-5732
89. Min L, Li-Li Z, Jun-Wei G, Xin-Yuan Q, Yi-Jing L, Di-Qiu L (2012) Immunogenicity of Lactobacillus-expressing VP2 and VP3 of the infectious pancreatic necrosis virus (IPNV) in rainbow trout. Fish Shellfish Immunol 32:196-203
90. Zhao LL, Liu M, Ge JW, Qiao XY, Li YJ, Liu DQ (2012) Expression of infectious pancreatic necrosis virus (IPNV) VP2-VP3 fusion protein in Lactobacillus casei and immunogenicity in rainbow trouts. Vaccine 30:1823-1829
91. Wang Z, Gao J, Yu Q, Yang Q (2012) Oral immunization with recombinant Lactococcus lactis expressing the hemagglutinin of the avian influenza virus induces mucosal and systemic immune responses. Future Microbiol 7:1003-1010
92. Liu DQ, Ge JW, Qiao XY, Jiang YP, Liu SM, Li YJ (2012) High-level mucosal and systemic immune responses induced by oral administration with Lactobacillus-expressed porcine epidemic diarrhea virus (PEDV) S1 region combined with Lactobacillus-expressed N protein. Appl Microbiol Biotechnol 93:2437-2446
93. Ren C, Zhang Q, Wang G, Ai C, Hu M, Liu X, Tian F, Zhao J, Chen Y, Wang M et al (2014) Modulation of peanut-induced allergic immune responses by oral lactic acid bacteria-based vaccines in mice. Appl Microbiol Biotechnol 98:6353-6364
94. Ai C, Zhang Q, Ren C, Wang G, Liu X, Tian F, Zhao J, Zhang H, Chen YQ, Chen W (2014) Genetically engineered Lactococcus lactis protect against house dust mite allergy in a BALB/c mouse model. PLoS One 9:e109461
95. An HM, Park SY, Lee do K, Kim JR, Cha MK, Lee SW, Lim HT, Kim KJ, Ha NJ (2011) Antiobesity and lipid-lowering effects of Bifidobacterium spp. in high fat diet-induced obese rats. Lipids Health Dis 10:116
96. Yin YN, Yu QF, Fu N, Liu XW, Lu FG (2010) Effects of four Bifidobacteria on obesity in high-fat diet induced rats. World J Gastroenterol 16:3394-3401
97. Bermudez-Humaran LG, Nouaille S, Zilberfarb V, Corthier G, Gruss A, Langella P, Issad T (2007) Effects of intranasal administration of a leptin-secreting Lactococcus lactis recombinant on food intake, body weight, and immune response of mice. Appl Environ Microbiol 73:5300-5307
98. Frossard CP, Steidler L, Eigenmann PA (2007) Oral administration of an IL-10-secreting Lactococcus lactis strain prevents food-induced IgE sensitization. J Allergy Clin Immunol 119:952-959
99. Wu C, Yang G, Bermudez-Humaran LG, Pang Q, Zeng Y, Wang J, Gao X (2006) Immunomodulatory effects of IL-12 secreted by Lactococcus lactis on Th1/Th2 balance in ovalbumin (OVA)-induced asthma model mice. Int Immunopharmacol 6:610-615
100. de Azevedo MSP, Innocentin S, Dorella FA, Rocha CS, Mariat D, Pontes DS, Miyoshi A, Azevedo V, Langella P, Chatel JM (2013) Immunotherapy of allergic diseases using probiotics or recombinant probiotics. J Appl Microbiol 115:319-333
101. Jenkins N (2007) Modifications of therapeutic proteins: challenges and prospects. Cytotechnology 53:121-125
102. Blanquet S, Antonelli R, Laforet L, Denis S, Marol-Bonnin S, Alric M (2004) Living recombinant Saccharomyces cerevisiae secreting proteins or peptides as a new drug delivery system in the gut. J Biotechnol 110:37-49
103. Peterbauer C, Maischberger T, Haltrich D (2011) Food-grade gene expression in lactic acid bacteria. Biotechnol J 6:1147-1161
104. Didari T, Solki S, Mozaffari S, Nikfar S, Abdollahi M (2014) A systematic review of the safety of probiotics. Expert Opin Drug Saf 13:227-239
105. Doron S, Snydman DR (2015) Risk and safety of probiotics. Clin Infect Dis 60(Suppl 2):S129-S134
106. Ishibashi N, Yamazaki S (2001) Probiotics and safety. Am J Clin Nutr 73:465S-470S
107. Plaza-Diaz J, Gomez-Llorente C, Fontana L, Gil A (2014) Modulation of immunity and inflammatory gene expression in the gut, in inflammatory diseases of the gut and in the liver by probiotics. World J Gastroenterol 20:15632-15649
108. Villena J, Aso H, Kitazawa H (2014) Regulation of toll-like receptors-mediated inflammation by immunobiotics in bovine intestinal epitheliocytes: role of signaling pathways and negative regulators. Front Immunol 5:421
109. Yu Z, Huang Z, Sao C, Huang Y, Zhang F, Ma G, Chen Z, Zeng Z, Qiwen D, Zeng W (2013) Oral immunization of mice using Bifidobacterium longum expressing VP1 protein from enterovirus 71. Arch Virol 158:1071-1077
110. Takei S, Omoto C, Kitagawa K, Morishita N, Katayama T, Shigemura K, Fujisawa M, Kawabata M, Hotta H, Shirakawa T (2014) Oral administration of genetically modified Bifidobacterium displaying HCV-NS3 multi-epitope fusion protein could induce an HCV-NS3-specific systemic immune response in mice. Vaccine 32:3066-3074
111. Medaglini D, Ciabattini A, Spinosa MR, Maggi T, Marcotte H, Oggioni MR, Pozzi G (2001) Immunization with recombinant Streptococcus gordonii expressing tetanus toxin fragment C confers protection from lethal challenge in mice. Vaccine 19:1931-1939
112. Marelli B, Perez AR, Banchio C, de Mendoza D, Magni C (2011) Oral immunization with live Lactococcus lactis expressing rotavirus VP8 subunit induces specific immune response in mice. J Virol Methods 175:28-37
113. Hanniffy SB, Carter AT, Hitchin E, Wells JM (2007) Mucosal delivery of a pneumococcal vaccine using Lactococcus lactis affords protection against respiratory infection. J Infect Dis 195:185-193
114. Lee JS, Poo H, Han DP, Hong SP, Kim K, Cho MW, Kim E, Sung MH, Kim CJ (2006) Mucosal immunization with surface-displayed severe acute respiratory syndrome coronavirus spike protein on Lactobacillus casei induces neutralizing antibodies in mice. J Virol 80:4079-4087
115. Sun P, Zhang X, Zang X, Zhou X, Chen Y, Arunakumara KK, Liang B (2007) Anti-hypercalcemic effect of orally administered recombinant Saccharomyces cerevisiae expressing salmon calcitonin on hypercalcemic rats. Biotechnol Lett 29:1013-1018